Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Operating Leases (2023 - 2025)

Historic Operating Leases for bioAffinity Technologies (BIAF) over the last 3 years, with Q3 2025 value amounting to $375139.0.

  • bioAffinity Technologies' Operating Leases fell 2494.95% to $375139.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $375139.0, marking a year-over-year decrease of 2494.95%. This contributed to the annual value of $469596.0 for FY2024, which is 2432.75% up from last year.
  • bioAffinity Technologies' Operating Leases amounted to $375139.0 in Q3 2025, which was down 2494.95% from $407313.0 recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' Operating Leases ranged from a high of $499849.0 in Q3 2024 and a low of $331307.0 during Q2 2024
  • In the last 3 years, bioAffinity Technologies' Operating Leases had a median value of $398260.0 in 2023 and averaged $405852.3.
  • As far as peak fluctuations go, bioAffinity Technologies' Operating Leases surged by 2550.82% in 2024, and later plummeted by 2494.95% in 2025.
  • Quarter analysis of 3 years shows bioAffinity Technologies' Operating Leases stood at $377709.0 in 2023, then increased by 24.33% to $469596.0 in 2024, then decreased by 20.11% to $375139.0 in 2025.
  • Its Operating Leases was $375139.0 in Q3 2025, compared to $407313.0 in Q2 2025 and $438757.0 in Q1 2025.